DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma; Ocular Hypertension

Intervention: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops (Drug); latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Affairs, Study Director, Affiliation: Allergan


Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0. 005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0. 1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0. 005%

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: IOP

Secondary outcome: Tolerability


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Glaucoma or ocular hypertension in both eyes

- Currently being treated with latanoprost 0. 005% QD

- IOP greater than or equal to 18mm Hg on latanoprost 0. 005%

- Best-corrected VA of 20/200 or better in each eye

- Visual field within 6 months of study entry

Exclusion Criteria:

- Secondary glaucoma

- Active intraocular inflammation or macular edema

- Intraocular surgery or laser surgery within the past 3 months

Locations and Contacts

Atlanta, Georgia, United States
Additional Information

Starting date: July 2006
Last updated: December 26, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017